TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20539274

Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (Atropine and Fentanyl without Rocuronium)
Number of subjects: 44
Study: 19038683

Group type: EXPERIMENTAL
Intervention: Controlled release of bFGF
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Controlled release of bFGF combined with hCDCs
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Controlled release of bFGF combined with bone marrow-derived mesenchymal stem cells
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo medium
Number of subjects: 40
Study: 16758263

Group type: EXPERIMENTAL
Intervention: Itraconazole (100 mg, first dose 200 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Gemfibrozil (600 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of itraconazole and gemfibrozil
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 12890944

Group type: EXPERIMENTAL
Intervention: Postnatal steroid therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Guidelines for steroid use by the American Academy of Pediatrics and the Canadian Paediatric Society
Number of subjects: 0
Study: 10864186

Group type: EXPERIMENTAL
Intervention: Supervision by lay health worker (LHW)
Number of subjects: 156
Study: 9103732

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management (CBSM) intervention for 10 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Modified waiting-list control group
Number of subjects: 0
Study: 1555313

Group type: EXPERIMENTAL
Intervention: mainly rough food
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: mainly soft food
Number of subjects: 150

Group type: COMPARATOR
Intervention: no advice except to eat regularly
Number of subjects: 150
Study: 6376596

Group type: EXPERIMENTAL
Intervention: Nifedipine withdrawal
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo withdrawal
Number of subjects: 81
Study: 31675957

Group type: EXPERIMENTAL
Intervention: Multicomponent knowledge transfer intervention including educational group programme, decision support tool, and quarterly feedback report.
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Multicomponent knowledge transfer intervention.
Number of subjects: 412
Study: 29177955

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate 6 g daily (N = 17)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (N = 18)
Number of subjects: 35
Study: 27053380

Group type: EXPERIMENTAL
Intervention: Maternal LCPUFA supplementation (1020 mg DHA plus 180 mg EPA/d)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Maternal LCPUFA supplementation
Number of subjects: 112
Study: 25452635

Group type: EXPERIMENTAL
Intervention: Total Contact Cast (TCC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pressure-Relieving Ankle Foot Orthosis (PRAFO)
Number of subjects: 30
Study: 22377512

Group type: EXPERIMENTAL
Intervention: Paliperidone ER (3-12 mg/day)
Number of subjects: 766

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 766

Group type: COMPARATOR
Intervention: Olanzapine (5-20 mg/day)
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Number of subjects: 766

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 766
Study: 20223994

Group type: EXPERIMENTAL
Intervention: Exercise plus volume infusion (dextran)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Exercise alone
Number of subjects: 21

Group type: COMPARATOR
Intervention: Volume infusion alone (dextran)
Number of subjects: 21
Study: 18551025

Group type: EXPERIMENTAL
Intervention: Increased left atrial systolic force (>14.33 kdyn)
Number of subjects: 567

Group type: COMPARATOR
Intervention: Normal left atrial systolic force (≤14.33 kdyn)
Number of subjects: 567
Study: 16004662

Group type: EXPERIMENTAL
Intervention: Advance leaflet containing advice on reducing alcohol intake
Number of subjects: 361
Study: 11952026

Group type: EXPERIMENTAL
Intervention: IM ertapenem 1 g once daily
Number of subjects: 117

Group type: COMPARATOR
Intervention: IM ceftriaxone 1 g once daily
Number of subjects: 117
Study: 10075344

Group type: EXPERIMENTAL
Intervention: 5 g raw flaxseed
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 15 g raw flaxseed
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 25 g raw flaxseed
Number of subjects: 9

Group type: COMPARATOR
Intervention: 25 g processed flaxseed (muffin or bread)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 25 g flaxseed (raw or processed)
Number of subjects: 9
Study: 7722978

Group type: EXPERIMENTAL
Intervention: Double-balloon device with prostaglandin E2 (PGE2) instillation
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2)
Number of subjects: 340
Study: 2027481

Group type: EXPERIMENTAL
Intervention: Low-dose prednisone (0.75 mg/kg/d)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: High-dose prednisone (1.5 mg/kg/d)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 6418647

Group type: EXPERIMENTAL
Intervention: Occupational health nurses (OHNs) monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular care (RC) in the community
Number of subjects: 0
Study: 30651222

Group type: COMPARATOR
Intervention: SIT (sitting on an office chair)
Number of subjects: 20

Group type: COMPARATOR
Intervention: SIT-ACTIVE (sitting on a stability ball)
Number of subjects: 20

Group type: COMPARATOR
Intervention: SIT-STAND (sitting with hourly 10-min standing interruptions)
Number of subjects: 20
Study: 30010104

Group type: EXPERIMENTAL
Intervention: Bridging exercise with abdominal drawing-in maneuver (ADIM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bridging exercise without abdominal drawing-in maneuver (ADIM)
Number of subjects: 20
Study: 27693664

Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Number of subjects: 778

Group type: COMPARATOR
Intervention: Control
Number of subjects: 778
Study: 25212541

Group type: EXPERIMENTAL
Intervention: Pharmacist counselling before starting chemotherapy
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Quality of information
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Cost of pharmacist counselling
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Follow-up with the pharmacist after starting chemotherapy
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Attitude of pharmacist
Number of subjects: 280
Study: 23064532

Group type: EXPERIMENTAL
Intervention: Home-based screening
Number of subjects: 200

Group type: COMPARATOR
Intervention: Clinic-based screening
Number of subjects: 200
Study: 19274623

Group type: EXPERIMENTAL
Intervention: Meaning Centered Group Psychotherapy (MCGP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Supportive Group Psychotherapy (SGP)
Number of subjects: 90
Study: 17114889

Group type: EXPERIMENTAL
Intervention: Sublingual-swallow immunotherapy (SLIT) with Juniperus ashei allergen extract
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 16394701

Group type: EXPERIMENTAL
Intervention: 50 mg rofecoxib
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 550 mg naproxen
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15383182

Group type: EXPERIMENTAL
Intervention: Captodiamine (150 mg/d)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 10735891

Group type: EXPERIMENTAL
Intervention: Suramin plus hydrocortisone (HC, 40 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus hydrocortisone (HC)
Number of subjects: 0
Study: 8923333

Group type: EXPERIMENTAL
Intervention: 12.5 mg of doxylamine succinate administered orally every 6 h for 17 days
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 30 mg of phenobarbital administered orally every 6 h for 17 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo administered orally every 6 h for 17 days
Number of subjects: 48
Study: 1557982

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: No Timolol
Number of subjects: 0
Study: 4053337

Group type: EXPERIMENTAL
Intervention: Slow inspiratory flow rates (15-30 l/min)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Flow rates higher than 70 l/min
Number of subjects: 15
Study: 31242792

Group type: COMPARATOR
Intervention: Indacaterol/Glycopyrrolate (IND/GLY) 27.5/15.6 µg twice daily
Number of subjects: 2043

Group type: COMPARATOR
Intervention: Indacaterol/Glycopyrrolate (IND/GLY)
Number of subjects: 2043
Study: 28987994

Group type: EXPERIMENTAL
Intervention: Delta tACS (2.5Hz)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Theta tACS (5Hz)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham tACS
Number of subjects: 24
Study: 26250523

Group type: EXPERIMENTAL
Intervention: Thymosin α1 (Tα1) plus routine treatment
Number of subjects: 84

Group type: COMPARATOR
Intervention: Routine treatment (Control group)
Number of subjects: 84
Study: 24081937

Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg once per day
Number of subjects: 1074

Group type: COMPARATOR
Intervention: Sorafenib 400 mg twice per day
Number of subjects: 1074
Study: 21694621

Group type: EXPERIMENTAL
Intervention: Antidepressant use (citalopram, sertraline, paroxetine)
Number of subjects: 281

Group type: COMPARATOR
Intervention: No antidepressant use
Number of subjects: 281
Study: 18582178

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 5 mg MPH
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 10 mg MPH
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 15 mg MPH
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 20 mg MPH
Number of subjects: 65
Study: 16538239

Group type: EXPERIMENTAL
Intervention: Olibra fat emulsion (5 g of Olibra fat)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (5 g milk fat)
Number of subjects: 28
Study: 12740736

Group type: EXPERIMENTAL
Intervention: Sprint trained runners
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Endurance trained runners
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Untrained subjects
Number of subjects: 3
Study: 11069454

Group type: EXPERIMENTAL
Intervention: Red light (630 +/- 15 nm)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Green light (540 +/- 15 nm)
Number of subjects: 61
Study: 8836933

Group type: EXPERIMENTAL
Intervention: Sustained-release (SR) levodopa preparation (100 mg and 200 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional immediate-release (IR) levodopa preparation (100 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of SR and IR levodopa (70% SR and 30% IR)
Number of subjects: 12
Study: 1417666

Group type: EXPERIMENTAL
Intervention: Vitamin E administration at a dose of 100 mg daily for three weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Vitamin A administration
Number of subjects: 32
Study: 3883876

Group type: EXPERIMENTAL
Intervention: High pressure compression stocking
Number of subjects: 303

Group type: COMPARATOR
Intervention: Standard bandaging technique
Number of subjects: 303
Study: 30915676

Group type: EXPERIMENTAL
Intervention: Cervical cancer education delivered by bilingual community health educators
Number of subjects: 1488

Group type: COMPARATOR
Intervention: General health education including information about cancer screening
Number of subjects: 1488
Study: 29895599

Group type: EXPERIMENTAL
Intervention: Activated Clotting Time (ACT) >230 s
Number of subjects: 3275

Group type: EXPERIMENTAL
Intervention: ACT ≥250 s (femoral approach)
Number of subjects: 3275

Group type: EXPERIMENTAL
Intervention: ACT ≥290 s (radial approach)
Number of subjects: 3275
Study: 27716694

Group type: EXPERIMENTAL
Intervention: Goal-Directed Therapy (GDT)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control
Number of subjects: 130
Study: 24474602

Group type: EXPERIMENTAL
Intervention: TAU+P (treatment as usual combined with clinician-lead cognitive behavioural treatment for perfectionism)
Number of subjects: 61

Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 61
Study: 21965526

Group type: EXPERIMENTAL
Intervention: Aliskiren (direct renin inhibitor), n=423
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Aliskiren (direct renin inhibitor)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Placebo, n=397
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 214
Study: 19147800

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: Social Behaviour and Network Therapy (SBNT)
Number of subjects: 742

Group type: COMPARATOR
Intervention: Both MET and SBNT
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: Clients
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: Therapists
Number of subjects: 742
Study: 17398122

Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 3244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3244
Study: 15198280

Group type: EXPERIMENTAL
Intervention: Moving textbox instruments
Number of subjects: 5

Group type: COMPARATOR
Intervention: Heading indicator (control)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Workload
Number of subjects: 5

Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 5
Study: 11765586

Group type: EXPERIMENTAL
Intervention: Metformin (2 × 850 mg/day)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Acarbose (3 × 100 mg/day)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Lifestyle modifications (control group)
Number of subjects: 2
Study: 9164900

Group type: EXPERIMENTAL
Intervention: Isometric handgrip exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 0
Study: 8388880

Group type: EXPERIMENTAL
Intervention: naloxone
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: nifedipine/naloxone
Number of subjects: 7
Study: 3828166

Group type: EXPERIMENTAL
Intervention: Continuous bilateral intercostal blockade
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional i.v. narcotics
Number of subjects: 0
Study: 30602756

Group type: COMPARATOR
Intervention: tIOL
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: PCRI
Number of subjects: 80
Study: 28642330

Group type: EXPERIMENTAL
Intervention: Systolic BP target of <120 mm Hg (intensive group)
Number of subjects: 2646

Group type: COMPARATOR
Intervention: Systolic BP target of <140 mm Hg (standard group)
Number of subjects: 2646
Study: 26614412

Group type: EXPERIMENTAL
Intervention: TAVR (self-expanding bioprosthesis)
Number of subjects: 742

Group type: COMPARATOR
Intervention: SAVR (surgical aortic valve replacement)
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 742

Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: All patients with severe PPM (TAVR + SAVR)
Number of subjects: 742
Study: 24450891

Group type: EXPERIMENTAL
Intervention: Bapineuzumab
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Bapineuzumab (0.5 mg/kg)
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Bapineuzumab (1.0 mg/kg)
Number of subjects: 1090

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1090
Study: 21848927

Group type: EXPERIMENTAL
Intervention: GAD-alum treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 19410984

Group type: EXPERIMENTAL
Intervention: Silicone metacarpophalangeal joint arthroplasty (SMPA)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 163
Study: 17138955

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 420
Study: 15871755

Group type: COMPARATOR
Intervention: Standard verbal counseling (A)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Verbal counseling with emphasis on Turbuhaler position during priming (B)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Augmented verbal counseling plus physical demonstration (C)
Number of subjects: 26
Study: 12475829

Group type: EXPERIMENTAL
Intervention: Enoxaparin, 40 mg/d
Number of subjects: 150

Group type: COMPARATOR
Intervention: Heparin, 5,000 U bid
Number of subjects: 150
Study: 10597852

Group type: EXPERIMENTAL
Intervention: Grade 3 intrameniscal signal abnormalities in gymnasts
Number of subjects: 24
Study: 8950073

Group type: EXPERIMENTAL
Intervention: Elgodipine (64 micrograms/kg, i.v.)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 1683354

Group type: EXPERIMENTAL
Intervention: Etilefrin (Effortil)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Ornithine 8 vasopressin (Por 8)
Number of subjects: 33
Study: 6957982

Group type: EXPERIMENTAL
Intervention: 50 mg PIR twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 20
Study: 31207152

Group type: EXPERIMENTAL
Intervention: Live Zoster Vaccine (LZV)
Number of subjects: 1146

Group type: COMPARATOR
Intervention: Tofacitinib 5 mg BID
Number of subjects: 1146

Group type: COMPARATOR
Intervention: Tofacitinib 5 mg BID plus MTX
Number of subjects: 1146

Group type: COMPARATOR
Intervention: Adalimumab (ADA) 40 mg every other week plus MTX
Number of subjects: 1146

Group type: EXPERIMENTAL
Intervention: LZV
Number of subjects: 1146
Study: 30292744

Group type: EXPERIMENTAL
Intervention: Brincidofovir
Number of subjects: 452

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 452
Study: 28134783

Group type: EXPERIMENTAL
Intervention: Training and support
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: Financial reimbursement
Number of subjects: 756
Study: 25228065

Group type: EXPERIMENTAL
Intervention: Emotion-focused decision aid with affective content
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Information-focused decision aid without affective content
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control condition (no affective content)
Number of subjects: 148
Study: 23407784

Group type: EXPERIMENTAL
Intervention: Syndrome 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Syndrome 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Syndrome 3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All 3 syndrome groups
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 21158931

Group type: EXPERIMENTAL
Intervention: All-ceramic crowns
Number of subjects: 20

Group type: COMPARATOR
Intervention: Porcelain-fused-to-ceramic (PFM) crowns
Number of subjects: 20
Study: 19140095

Group type: EXPERIMENTAL
Intervention: 360 mg verapamil daily for 6 days
Number of subjects: 18
Study: 17712295

Group type: EXPERIMENTAL
Intervention: BAT Ultrasound (Nomos, Sewicky, PA)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Computed Tomography (CT)
Number of subjects: 15
Study: 15562168

Group type: EXPERIMENTAL
Intervention: Inspiratory resistive loading (IRL) set at 80% of maximum inspiratory pressure, three days a week for 10 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo group (PLA) performing the same training procedure with minimal resistance
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (CON) performing no IRL during the 10 week study period
Number of subjects: 15
Study: 10750752

Group type: EXPERIMENTAL
Intervention: hANP (human atrial natriuretic peptide) administered for 24 hours from the start of CPB
Number of subjects: 40

Group type: COMPARATOR
Intervention: non-hANP group (control)
Number of subjects: 40
Study: 8669670

Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg/kg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Etomidate (0.4 mg/kg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Thiopental (5 mg/kg)
Number of subjects: 75
Study: 1529939

Group type: EXPERIMENTAL
Intervention: Fruits and vegetables (administered for 12 weeks)
Number of subjects: 621

Group type: COMPARATOR
Intervention: Control group (no fruits and vegetables)
Number of subjects: 621
Study: 4074606

Group type: EXPERIMENTAL
Intervention: Felodipine 10 mg oral solution
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 3304706

Group type: EXPERIMENTAL
Intervention: Timolol (5.5 mg iv as a bolus divided into four doses during the first 2 hours followed by 10 mg orally twice daily for 1 month)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 200
Study: 30197041

Group type: EXPERIMENTAL
Intervention: PSA-TRICOM (PROSTVAC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28288611

Group type: EXPERIMENTAL
Intervention: Resistance exercise (twice weekly for 15 weeks)
Number of subjects: 43
Study: 25774705

Group type: EXPERIMENTAL
Intervention: Low-glycaemic-index (LGI) diet and Policaptil Gel Retard
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Low-glycaemic-index (LGI) diet
Number of subjects: 133

Group type: COMPARATOR
Intervention: Energy-restricted diet (ERD)
Number of subjects: 133
Study: 23690414

Group type: EXPERIMENTAL
Intervention: Methylphenidate + Nursing Telephone Intervention (MP+NTI)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Placebo + Nursing Telephone Intervention (PL+NTI)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Methylphenidate + Control Telephone Intervention (MP+CTI)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Placebo + Control Telephone Intervention (PL+CTI)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Nursing Telephone Intervention (NTI)
Number of subjects: 141
Study: 20534951

Group type: EXPERIMENTAL
Intervention: Oral itraconazole solution mixed with orange juice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral itraconazole solution with water
Number of subjects: 0
Study: 18503623

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 3 mg/mL
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ropivacaine 4.5 mg/mL
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Bupivacaine 3 mg/mL
Number of subjects: 45
Study: 16803518

Group type: EXPERIMENTAL
Intervention: Telomerase activity in tumor
Number of subjects: 33

Group type: COMPARATOR
Intervention: Telomerase activity in anterior vaginal margin (AVM) and posterior vaginal margin (PVM)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Telomerase activity in PVM
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Presence of HPV in AVM or PVM
Number of subjects: 33